Table 3.
Medications and electrolyte abnormalities in patients with COVID-19 and QT prolongation
| Factor | Value |
|---|---|
| Patients with QT-prolonging medications | 103 (100) |
| COVID-19–related medications | |
| Hydroxychloroquine | 98 (95.1) |
| Hydroxychloroquine + atazanavir | 21 (20.4) |
| Tocilizumab | 83 (80.6) |
| Methylprednisolone | 28 (27.2) |
| Other COVID-19–related medications | 7 (6.8) |
| Remdesivir | 5 (4.9) |
| Azithromycin | 3 (2.9) |
| Nivolumab | 2 (1.9) |
| Ritonavir/lopinavir | 2 (1.9) |
| Non-COVID-19–related medications | 62 (60.2) |
| Amiodarone | 7 (6.8) |
| Proton pump inhibitor | 18 (17.5) |
| Propofol | 16 (15.5) |
| Sedative | 14 (13.6) |
| SSRI | 11 (10.7) |
| Antipsychotic | 9 (8.7) |
| Antidepressant | 7 (6.8) |
| Tacrolimus | 7 (6.8) |
| Antibiotic | 7 (6.8) |
| Antiemetic | 6 (5.8) |
| Other QT-prolonging medications | 10 (9.7) |
| Electrolyte abnormalities | 50 (48.5) |
| Hypomagnesemia | 31 (30.1) |
| Hypokalemia | 27 (26.2) |
| Hypomagnesemia + hypokalemia | 9 (8.7) |
Values are presented as mean ± SD or as n (%).
Hypomagnesemia was defined as a value less than 2.0 mEq/L, and hypokalemia was defined as a value less than 4.0 mEq/L.
COVID-19 = coronavirus disease 2019; SSRI = selective serotonin reuptake inhibitor.